Miriam is the Chief Development Officer at Sapreme, bringing over 15 years of experience in translational science, RNA, and antibody therapeutics. At Sapreme, she leverages her expertise to lead the development of cutting-edge therapeutics that overcome the challenge of endosomal entrapment, paving the way for next-generation treatments. Throughout her career, Miriam has held leadership roles at leading organizations, including ProQR, Johnson & Johnson, and Crucell, where she spearheaded drug discovery and clinical development initiatives across rare and infectious disease programs.

Miriam earned her Ph.D. in Biochemistry from the University of Bristol, specializing in endosomal biology, and further honed her expertise as a postdoctoral fellow at Harvard University under the mentorship of Professor Xiaowei Zhuang.